Proteomics International Laboratories has released a groundbreaking study showing that its PromarkerD predictive test can effectively forecast renal decline in patients with type 1 diabetes. This exciting development, presented at the recent Australasian Diabetes Conference in Perth, marks a significant advancement in the early detection of chronic kidney disease (CKD), offering new hope to the millions living with type 1 diabetes globally.
PromarkerD, a blood test proven to predict kidney disease up to four years in advance in type 2 diabetes, has now shown the same high accuracy in type 1 diabetes. As part of the Fremantle Diabetes Study Phase II, PromarkerD successfully predicted kidney function decline in type 1 patients, making it the first test to demonstrate this level of accuracy for their specific clinical needs.
Professor Tim Davis, lead author of the study and a consultant physician at Fremantle Hospital, emphasised the significance of early detection for type 1 diabetes patients. By identifying at-risk individuals years before traditional methods, specialists can intervene sooner, potentially preventing severe renal complications and improving patient outcomes.
With diabetes affecting over 537 million people worldwide, and type 1 diabetes accounting for 10% of all cases, early detection of CKD could have profound global health implications. CKD remains one of the most serious complications of diabetes, often leading to end-stage renal disease, requiring dialysis or kidney transplantation. The PromarkerD test provides doctors with crucial information that could enable timely intervention and better management of kidney health.
Proteomics International Managing Director, Dr Richard Lipscombe, emphasised the study’s results as a significant advancement in diabetes care. “This groundbreaking result highlights the versatility and robustness of the PromarkerD test. We are excited about the potential impact this could have on managing kidney health in both type 1 and type 2 diabetes patients,” Dr Lipscombe said.
The successful application of PromarkerD in type 1 diabetes offers new hope for millions of patients worldwide. By predicting kidney disease years before symptoms appear, this innovative blood test could transform the management of diabetes, improving outcomes and quality of life for those at risk of CKD.
As PromarkerD continues to show promise in the fight against diabetic kidney disease, Proteomics International remains committed to pioneering new diagnostic solutions that enhance patient care and address critical global health challenges.